Mucoepidermoid Carcinoma: Symptoms, Diagnosis & Outlook

Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of the salivary glands, and it shows up most often as a painless lump near the ear or jaw, or as a firm swelling on the roof of the mouth. Outlook varies enormously depending on the tumor’s microscopic grade: low-grade tumors carry five-year survival rates well above 80%, while high-grade tumors behave far more aggressively. The gap between best and worst cases is wider than for many other cancers, which makes accurate grading and staging critical to every treatment decision that follows.

How It Typically Shows Up in Major Salivary Glands

The parotid gland, the large salivary gland just in front of each ear, is the single most common site. In a large Mayo Clinic series, nearly all patients presented with a mass in the parotid region, and most of the time that mass was painless.¹ About one in seven reported some pain or tenderness, and roughly one in fourteen had facial nerve weakness at the time of diagnosis. Skin ulceration, facial twitching, and a separate neck lump were all uncommon first symptoms.

Because the parotid gland wraps around the facial nerve, tumors in this location can affect the muscles that let you smile, close your eye, or raise your eyebrow. Facial nerve involvement is more likely with high-grade tumors, which tend to present at a more advanced stage.² Some parotid MECs grow slowly for months or years before anyone notices them; others declare themselves sooner with rapid growth or discomfort. In very rare cases, a parotid MEC can present as an outward-growing mass that breaks through the skin.³

When It Appears Inside the Mouth

The palate is the second most common location, arising from the hundreds of tiny minor salivary glands scattered throughout the mouth. A palatal MEC often looks deceptively harmless: a firm, painless bump on the hard palate that may have a bluish tint.⁴ Clinically, it can resemble a mucocele (a harmless mucus-filled cyst), a vascular lesion, or even a dental abscess.⁵ In children and adolescents, about a third of palatal MECs present as a soft, fluctuant swelling with surface color changes, making the resemblance to benign conditions even stronger.⁶

This is one reason oral lumps that persist for more than a couple of weeks deserve professional evaluation, even when they seem benign. A swelling that sits on a salivary-gland-bearing area of the mouth and does not resolve is not something to write off as a canker sore or cyst.

Getting to a Diagnosis

When a lump in the parotid or elsewhere raises suspicion, the workup typically combines imaging and tissue sampling. MRI is especially useful for parotid tumors because it shows soft-tissue detail better than CT. Researchers have identified MRI features that help distinguish MEC from other parotid masses, including cystic components within the tumor, certain signal patterns on different MRI sequences, and heterogeneous enhancement after contrast dye.⁷ A newer MRI-based scoring system that accounts for tumor size, shape, cystic component, margins, and necrosis has shown roughly 89% accuracy in predicting high-grade tumors before surgery.⁸

Fine needle aspiration (FNA), in which a thin needle draws cells from the mass, is commonly performed early in the evaluation. One study found that FNA achieved roughly 88% sensitivity and 100% specificity for identifying MEC preoperatively, meaning it rarely calls something MEC when it is not, though it occasionally misses the diagnosis.⁹ The definitive diagnosis, including the all-important grade, still comes from examining the surgically removed tumor under the microscope.

Why It Gets Mistaken for Other Things

Low-grade MEC is a well-known mimic. Because it can look like a simple cyst, a benign Warthin tumor, or a pleomorphic adenoma on imaging and even on initial needle biopsy, the correct diagnosis sometimes arrives only after surgical removal.¹⁰ At the other end of the spectrum, high-grade MEC can be difficult to distinguish from squamous cell carcinoma or adenosquamous carcinoma. Pathologists increasingly use a molecular test for a gene rearrangement called MAML2, which is present in most MECs but absent in the tumors that mimic them.¹¹ When morphology alone is ambiguous, this test can settle the question. Features like a tumor’s stroma, lymphoid tissue reactions, and unusual growth patterns all add to the diagnostic difficulty in borderline cases.¹²

How Grading Works and Why It Matters So Much

More than almost any other factor, the histological grade of a MEC determines what happens next: how aggressively the tumor is treated, whether radiation is added, and how likely the cancer is to come back. MEC is traditionally divided into three grades: low, intermediate, and high. Low-grade tumors tend to be partly cystic, with abundant mucus-producing cells. High-grade tumors are mostly solid, with fewer mucous cells, more abnormal-looking nuclei, higher rates of cell division, and sometimes necrosis or invasion into nerves and blood vessels.¹³

The trouble is that several competing grading systems exist, and they do not always agree. When the same set of tumors was re-graded using four commonly used systems, only about half scored the same across all of them. The biggest source of disagreement was the intermediate-grade category: features like solid growth pattern and tumor growth in nests and islands frequently pushed tumors from low to intermediate grade in some systems but not others.¹⁴ This inconsistency is clinically relevant because treatment recommendations differ for each tier. Some researchers have proposed simplifying to a two-tier system, defining high-grade as tumors with a high mitotic rate or necrosis, to reduce subjectivity. Using that approach, high-grade MEC accounted for fewer than 8% of cases.¹³

Regardless of which system is used, the clinical pattern is clear: patients with low- or intermediate-grade MEC have significantly better overall and disease-free survival than those with high-grade tumors, while there is little survival difference between the low and intermediate categories themselves.¹⁵

Treatment

Surgery is the cornerstone. For parotid tumors, the operation ranges from a superficial parotidectomy (removing the outer lobe) to a total parotidectomy, depending on tumor size and location. Whether the facial nerve can be preserved depends on whether the tumor has grown into or is merely touching the nerve. In low- and intermediate-grade cases, surgeons typically try to save the nerve even when the tumor is adherent to it; in high-grade cases, a nerve that is adherent or invaded is generally sacrificed along with the tumor.¹⁶

Neck dissection, in which lymph nodes in the neck are removed along with the primary tumor, is standard for high-grade MEC. For advanced (T3-T4) high-grade tumors, elective neck dissection even when there is no obvious lymph node involvement has been associated with markedly improved survival.¹⁷ For intermediate-grade MEC, the calculus is different. One study found that the rate of positive lymph node metastasis was only about 3% in intermediate-grade tumors, suggesting that routine neck dissection may not be warranted in most of these patients.¹⁸

Postoperative radiation is typically recommended for high-grade tumors, advanced-stage disease, or cases where surgical margins are positive (meaning cancer cells were found at the edge of the removed tissue).¹⁹ Combined surgery and postoperative radiation yields excellent long-term results overall, though high-grade tumors remain at significant risk for distant spread even with aggressive local treatment.²⁰

Outlook by Grade

The survival gap between grades is dramatic. In one study of patients treated with surgery and postoperative radiation, five-year overall survival was about 83% for those with non-high-grade tumors but only about 52% for those with high-grade tumors. High grade was the single strongest predictor of decreased survival on multivariate analysis, outweighing tumor size.²¹ In addition to grade, factors like age over 40, tumors that are fixed to surrounding tissue, and advanced T and N stage all independently predict worse outcomes.²²

Histological grade and positive lymph nodes are also the strongest predictors of recurrence. One analysis found that grade predicted both disease-free and overall survival, while positive nodes predicted disease-specific survival.²³ Low-grade MEC, when completely removed, has recurrence rates low enough that many patients are considered cured by surgery alone.

The CRTC1-MAML2 Fusion Gene

A chromosomal rearrangement that fuses two genes, CRTC1 and MAML2, is the most common molecular alteration in MEC. It is found in roughly two-thirds of all MECs and appears to be the primary driver of tumor formation. In a mouse model, switching on this fusion gene caused salivary gland tumors in every single animal, and blocking it shut down tumor growth in laboratory experiments.²⁴

Beyond its role in causing the cancer, the fusion has prognostic value. All low-grade MECs in one study carried the fusion, while only a minority of high-grade tumors did. Fusion-positive tumors had far fewer genomic abnormalities than fusion-negative ones, suggesting they are biologically simpler and less prone to aggressive behavior.²⁵ Knowing whether a tumor is fusion-positive or fusion-negative adds information beyond what the microscope alone can provide, particularly for intermediate-grade tumors where the clinical behavior is harder to predict.

MEC in Children and Adolescents

MEC is the most common salivary gland malignancy in children, just as it is in adults, but it behaves differently. Pediatric cases cluster in the low and intermediate grades and carry the CRTC1-MAML2 fusion at very high rates. One pediatric series found the fusion in 100% of cases tested.²⁶ Children more often present with a parotid gland mass, though palatal and submandibular tumors also occur.²⁷

Outcomes for children are consistently better than for adults. A comparative analysis using a national cancer database reported that the five-year cancer-specific survival in pediatric patients was about 98%, compared with roughly 89% in adults. The overall mortality rate was also substantially lower in the pediatric group.²⁸ Complete surgical excision alone is the standard treatment for children, with radiation generally reserved for the rare high-grade tumor with positive margins.

MEC Outside the Salivary Glands

Although salivary glands are the classic location, MEC can also arise in the lungs, specifically from the submucosal glands lining the airways. Pulmonary MEC accounts for a tiny fraction of all lung cancers but is the most common salivary-gland-type tumor found in the lung. Symptoms typically involve cough, hemoptysis, or recurrent pneumonia caused by airway obstruction rather than a palpable lump.²⁹

The same grading principle applies. In one series of 34 pulmonary MEC patients, lymph node metastasis was the strongest independent predictor of both overall survival and progression-free survival. Patients with low-grade tumors who underwent complete surgical removal and had no lymph node spread were effectively cured.³⁰ In older case reports of airway MEC, long-term survivors among low-grade patients averaged over a decade of follow-up, while the single high-grade case was fatal within about two years despite surgery and radiation.³¹

Radiation as a Risk Factor

Most MECs arise without any identifiable environmental cause, but prior radiation to the head and neck region is one recognized risk factor. Case reports have documented parotid MEC developing years or even decades after radiation therapy given for unrelated conditions, including radiation used to prevent keloid recurrence after ear surgery.³² In one such report, the tumor appeared ten years after treatment. Another case documented MEC arising twenty months after a second round of keloid radiation.³³ While the absolute risk from any individual course of radiation is very low, the pattern reinforces why exposure to the parotid region deserves long-term awareness.

What Targeted and Immune Therapies Might Offer

For advanced or recurrent high-grade MEC that cannot be controlled with surgery and radiation alone, treatment options have historically been limited. Standard chemotherapy has not proven highly effective in salivary gland cancers as a group. Attention has turned to molecular targets. The CRTC1-MAML2 fusion product itself activates a signaling pathway that drives tumor growth, making it a logical target for drug development.³⁴ High-grade tumors also tend to overexpress certain surface proteins, and some carry mutations that are already targeted by approved drugs regardless of tumor type. Pembrolizumab, for instance, is approved for tumors of any origin that have microsatellite instability, and larotrectinib or entrectinib can be used when an NTRK gene fusion is present.

Immune checkpoint therapy, which works by releasing the brakes on the immune system’s ability to attack cancer cells, is being explored as well. Research into MEC’s immune landscape has found that a subset of tumors, described as “immune-hot,” show elevated levels of PD-1, PD-L1, and other checkpoint molecules, implying these tumors might respond to checkpoint inhibitors.³⁵ Still, the actual rate of meaningful PD-L1 expression on tumor cells in MEC appears low overall, with one study finding it in fewer than one in ten cases of pulmonary MEC.³⁶ This is early-stage science, and no immunotherapy has yet become standard care for MEC. But for patients with recurrent high-grade disease that has exhausted conventional options, tumor profiling for actionable mutations is increasingly part of the conversation.

Life After Treatment

Surviving MEC does not always mean returning to how things were before. A multinational study of major salivary gland cancer survivors who were more than five years from diagnosis found that dry mouth was the most commonly reported long-term problem, mentioned by about a third of participants. Other frequent complaints included hearing impairment, soft tissue fibrosis, sticky saliva, and cranial nerve damage.³⁷ These side effects come from a combination of the surgery itself and radiation when it is given.

Quality-of-life studies in salivary gland carcinoma patients have consistently identified appearance concerns, reduced activity, and anxiety as the domains most affected. Facial nerve dysfunction, tumor stage, and whether postoperative radiation was given all influenced self-reported quality of life.³⁸ For patients who undergo facial nerve sacrifice, rehabilitation options including nerve grafting and physical therapy can help restore some function over time, but the recovery is slow and often incomplete. These practical realities deserve discussion before treatment begins, so patients and their families can plan for what recovery actually looks like.